Intrauterine insemination involves the injection of sperm into the uterine cavity and has the potential to be complicated by reproductive tract infections. There have been reports of pelvic infections associated with intrauterine insemination in foreign countries, but the incidence is low. Intraoperative asepsis and the addition of penicillin and streptomycin to the culture fluid can be effective in preventing infection. The application of Percoll and upstream methods can be more effective in reducing bacteria in semen. In addition, because intrauterine insemination is often treated with ovulation promotion, there is a risk of ovarian hyperstimulation syndrome, of which the incidence of severe hyperstimulation syndrome is about 1%. Multiple pregnancies and miscarriages are also one of the comorbidities. The incidence of multiple pregnancies and spontaneous miscarriages can be as high as 20% to 30% in patients with intrauterine insemination for pregnancy. The incidence of antisperm antibody formation in the female reproductive tract has also been reported, and the incidence of positive antisperm antibodies in women after intrauterine insemination is about 4% to 8%.